Kymera Therapeutics
Oral degrader company, mostly immunology, whose CDK2 molecular-glue degrader was optioned by Gilead in 2026 for CCNE1-driven cancers.
Gilead paid $40M for an option (June 2025) and exercised it for $45M (April 2026) on Kymera's preclinical CDK2 glue degrader (KT-200), aimed at CCNE1-amplified tumours and CDK4/6-inhibitor resistance. Kymera's own clinical pipeline (IRAK4, STAT6, TYK2) is immunological.
Pages like this
not linked directly; found by shared links- CompanyMonte Rosa Therapeutics
Shares Molecular glues that break the MYC-MAX partnership, Screen glue-like compounds against every cancer cell line and publish it, An open degrader consortium against every undruggable driver transcription factor, Design protein degraders small enough to get into the brain.
- CompanyNurix Therapeutics
Shares Find E3 ligases that only tumours have, and build degraders around them, Screen glue-like compounds against every cancer cell line and publish it, Design protein degraders small enough to get into the brain, Use antibodies to deliver protein-destroying drugs into the right cells.
- CompanyC4 Therapeutics
Shares Molecular glues that break the MYC-MAX partnership, Screen glue-like compounds against every cancer cell line and publish it, Design protein degraders small enough to get into the brain, Molecular glue discovery platforms.
- CompanyArvinas
Shares An open degrader consortium against every undruggable driver transcription factor, PROTACs & molecular glues (targeted protein degradation), The undruggable drivers, HR-positive / HER2-negative breast cancer.
- TechnologyDegrader-antibody conjugate (DAC)
Shares Use antibodies to deliver protein-destroying drugs into the right cells, Molecular glue discovery platforms, PROTACs & molecular glues (targeted protein degradation).
- Key paperThe first PROTAC: a chimeric molecule that tags a protein for destruction
Shares Molecular glue discovery platforms, PROTACs & molecular glues (targeted protein degradation), The undruggable drivers.
- CompanyTubulis (Gilead)
- IdeaDegrade the damaged p53 protein rather than trying to repair it
Shares PROTACs & molecular glues (targeted protein degradation), The undruggable drivers.